Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
electroCore, Inc. stock logo
ECOR
electroCore
$5.78
-4.1%
$7.93
$4.16
$10.49
$50.02M0.8888,479 shs73,441 shs
FOCL
FocalTherics
$5.44
-0.4%
$0.00
$1.21
$5.64
$204.65M-0.0443,187 shs21,812 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$1.02
-11.7%
$1.02
$0.90
$1.63
$233.53M1.071.93 million shs2.68 million shs
RxSight, Inc. stock logo
RXST
RxSight
$5.57
+6.1%
$5.31
$4.48
$13.22
$217.33M1.151.43 million shs2.37 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
electroCore, Inc. stock logo
ECOR
electroCore
-4.15%-12.95%-33.41%-11.08%-21.89%
FOCL
FocalTherics
-0.37%-0.73%+14.53%+543,999,900.00%+543,999,900.00%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-11.74%+2.50%-0.49%-18.80%-6.88%
RxSight, Inc. stock logo
RXST
RxSight
+6.10%+9.65%+19.02%-26.81%-23.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
electroCore, Inc. stock logo
ECOR
electroCore
$5.78
-4.1%
$7.93
$4.16
$10.49
$50.02M0.8888,479 shs73,441 shs
FOCL
FocalTherics
$5.44
-0.4%
$0.00
$1.21
$5.64
$204.65M-0.0443,187 shs21,812 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$1.02
-11.7%
$1.02
$0.90
$1.63
$233.53M1.071.93 million shs2.68 million shs
RxSight, Inc. stock logo
RXST
RxSight
$5.57
+6.1%
$5.31
$4.48
$13.22
$217.33M1.151.43 million shs2.37 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
electroCore, Inc. stock logo
ECOR
electroCore
-4.15%-12.95%-33.41%-11.08%-21.89%
FOCL
FocalTherics
-0.37%-0.73%+14.53%+543,999,900.00%+543,999,900.00%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-11.74%+2.50%-0.49%-18.80%-6.88%
RxSight, Inc. stock logo
RXST
RxSight
+6.10%+9.65%+19.02%-26.81%-23.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
electroCore, Inc. stock logo
ECOR
electroCore
2.00
Hold$18.00211.42% Upside
FOCL
FocalTherics
2.00
Hold$6.0010.29% Upside
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
2.60
Moderate Buy$4.19312.56% Upside
RxSight, Inc. stock logo
RXST
RxSight
1.92
Reduce$8.8959.59% Upside

Current Analyst Ratings Breakdown

Latest ECOR, RXST, FOCL, and LUCD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
FOCL
FocalTherics
Set Price Target$15.00
7/7/2026
RxSight, Inc. stock logo
RXST
RxSight
Set Price Target$6.50
7/7/2026
RxSight, Inc. stock logo
RXST
RxSight
Lower Price TargetUnderperform$8.00 ➝ $6.50
7/7/2026
RxSight, Inc. stock logo
RXST
RxSight
Reiterated RatingBuy$11.00
6/24/2026
electroCore, Inc. stock logo
ECOR
electroCore
Reiterated RatingSell (D-)
6/11/2026
RxSight, Inc. stock logo
RXST
RxSight
DowngradeSell (D-)Sell (E+)
6/8/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Boost Price TargetBuy$9.00 ➝ $9.25
6/2/2026
FOCL
FocalTherics
Reiterated RatingBuy$10.00
5/22/2026
RxSight, Inc. stock logo
RXST
RxSight
UpgradeSell (E+)Sell (D-)
5/15/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Lower Price TargetBuy$3.00 ➝ $2.00
5/15/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingBuy$2.50
(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
electroCore, Inc. stock logo
ECOR
electroCore
$32.03M1.50N/AN/A($0.21) per share-27.52
FOCL
FocalTherics
$70.53M2.89N/AN/A$0.52 per share10.46
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$4.71M43.76N/AN/A($0.31) per share-3.27
RxSight, Inc. stock logo
RXST
RxSight
$134.48M1.71N/AN/A$6.70 per share0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
electroCore, Inc. stock logo
ECOR
electroCore
-$13.97M-$1.77N/AN/AN/A-44.08%-1,956.38%-83.30%8/5/2026 (Estimated)
FOCL
FocalTherics
-$29.25M-$0.81N/AN/AN/A-41.47%-137.61%-40.62%8/27/2026 (Estimated)
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$58.01M-$0.47N/AN/AN/A-876.72%N/A-116.26%8/12/2026 (Estimated)
RxSight, Inc. stock logo
RXST
RxSight
-$38.94M-$1.13N/AN/AN/A-36.58%-17.01%-15.12%8/5/2026 (Estimated)

Latest ECOR, RXST, FOCL, and LUCD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$0.04N/AN/AN/A$1.43 millionN/A
8/5/2026Q2 2026
electroCore, Inc. stock logo
ECOR
electroCore
-$0.41N/AN/AN/A$9.49 millionN/A
8/5/2026Q2 2026
RxSight, Inc. stock logo
RXST
RxSight
-$0.21N/AN/AN/A$32.47 millionN/A
5/13/2026Q1 2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$0.05-$0.07-$0.02-$0.17$1.38 million$1.26 million
5/7/2026Q1 2026
FOCL
FocalTherics
-$0.22-$0.24-$0.02-$0.24$19.46 million$20.48 million
5/6/2026Q1 2026
electroCore, Inc. stock logo
ECOR
electroCore
-$0.59-$0.59N/A-$0.59$9.01 million$9.58 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
electroCore, Inc. stock logo
ECOR
electroCore
N/AN/AN/AN/AN/A
FOCL
FocalTherics
N/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/AN/AN/AN/AN/A
RxSight, Inc. stock logo
RXST
RxSight
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
electroCore, Inc. stock logo
ECOR
electroCore
N/A
1.02
0.86
FOCL
FocalTherics
1.79
1.34
0.99
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/A
1.07
1.05
RxSight, Inc. stock logo
RXST
RxSight
N/A
10.20
8.93

Institutional Ownership

CompanyInstitutional Ownership
electroCore, Inc. stock logo
ECOR
electroCore
26.74%
FOCL
FocalTherics
62.74%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
74.01%
RxSight, Inc. stock logo
RXST
RxSight
78.78%

Insider Ownership

CompanyInsider Ownership
electroCore, Inc. stock logo
ECOR
electroCore
13.80%
FOCL
FocalTherics
10.10%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
6.90%
RxSight, Inc. stock logo
RXST
RxSight
10.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
electroCore, Inc. stock logo
ECOR
electroCore
508.30 million7.15 millionNot Optionable
FOCL
FocalTherics
23037.48 million33.70 millionN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
70203.07 million189.06 millionNo Data
RxSight, Inc. stock logo
RXST
RxSight
22041.40 million37.24 millionOptionable

Recent News About These Companies

Ron Kurtz Steps Down as RxSight CEO
Piper Sandler Keeps Their Hold Rating on RxSight (RXST)
Wells Fargo Sticks to Its Hold Rating for RxSight (RXST)
RxSight Announces Preliminary Q2 Results
RxSight Stock (NASDAQ:RXST) Insider Trades

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
electroCore stock logo

electroCore NASDAQ:ECOR

$5.78 -0.25 (-4.15%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$5.90 +0.12 (+2.08%)
As of 07/16/2026 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

FocalTherics NASDAQ:FOCL

$5.44 -0.02 (-0.37%)
As of 07/16/2026 04:00 PM Eastern

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Lucid Diagnostics stock logo

Lucid Diagnostics NASDAQ:LUCD

$1.01 -0.14 (-11.74%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$1.06 +0.04 (+3.94%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

RxSight stock logo

RxSight NASDAQ:RXST

$5.57 +0.32 (+6.10%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$5.46 -0.11 (-1.97%)
As of 07:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.